Exelixis hits 25-year high after lifting 2025 revenue forecast

Exelixis

14/05/2025 15:26

Updates

** Shares of cancer drugmaker Exelixis EXEL.O rise as much as 19.2% to near 25-year high of $45.29

 ** Stock is set for its best day in over five years, if gains hold

** Co late on Tuesday raised 2025 rev. forecast between $2.25 billion and $2.35 billion, compared with prior view of between $2.15 billion and $2.25 billion

** Co posted Q1 total rev. of $555.4 million, beating analysts' estimate of $498.2 million - data compiled by LSEG

** Co posted Q1 adj. profit of 62 cents per share vs estimates of 36 cents per share on sales of its cancer drug, Cabometyx

** Including session's moves, stock up 31.8% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))